| Literature DB >> 23237591 |
Samar Abd ElHafeez1, Sunny A Sallam, Zahira M Gad, Carmine Zoccali, Claudia Torino, Giovanni Tripepi, Hala S ElWakil, Noha M Awad.
Abstract
BACKGROUND: Health Related Quality of Life (HRQOL) instruments need disease and country specific validation. In Arab countries, there is no specific validated questionnaire for assessment of HRQOL in chronic kidney disease (CKD) patients. The aim of this study was to present an Arabic translation, adaptation, and the subsequent validation of the kidney disease quality of life-short form (KDQOL-SFTM) version 1.3 questionnaire in a representative series of Egyptian CKD patients.Entities:
Mesh:
Year: 2012 PMID: 23237591 PMCID: PMC3583144 DOI: 10.1186/1471-2369-13-170
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Description and reliability of the Arabic version of KDQOL-SFversion 1.3 among the 100 CKD patients
| · | 77.50 (11.5) | 1.0 | 0.0 | 0.93 | 0.81 |
| · | 73.84 (13.6) | 2.0 | 0.0 | 0.88 | 0.73 |
| · | 40.13 (26.6) | 0.0 | 4.0 | 0.85 | 0.88 |
| · | 49.00 (38.3) | 18.0 | 40.0 | 0.93 | 0.28 |
| · | 68.73 (13.7) | 0.0 | 0.0 | 0.93 | 0.60 |
| · | 71.40 (10.4) | 0.0 | 0.0 | 0.92 | 0.23 |
| · | 61.50 (23.1) | 0.0 | 16.0 | 0.95 | 0.90 |
| · | 58.38 (15.9) | 0.0 | 0.0 | 0.93 | 0.90 |
| · | 63.17 (28.9) | 17.0 | 6.0 | 0.79 | 0.88 |
| · | 65.67 (17.9) | 5.0 | 0.0 | 0.94 | - |
| · | 49.10 (27.3) | 2.0 | 5.0 | 0.93 | 0.95 |
| · | 28.50 (32.0) | 5.0 | 48.0 | 0.88 | 0.76 |
| · | 44.65 (23.1) | 1.0 | 5.0 | 0.94 | 0.87 |
| · | 37.50 (19.0) | 0.0 | 0.0 | 0.92 | 0.83 |
| · | 60.84 (10.0) | 0.0 | 0.0 | 0.89 | 0.70 |
| · | 63.67 (41.9) | 50.0 | 24.0 | 0.86 | 0.83 |
| · | 54.50 (23.4) | 9.0 | 0.0 | 0.79 | 0.88 |
| · | 47.80 (14.5) | 0.0 | 0.0 | 0.94 | 0.81 |
| · | 57.40 (8.6) | 0.0 | 0.0 | 0.93 | 0.95 |
Comparison of the Arabic version of KDQOL-SF version 1.3 questionnaire scores for some demographic and clinical criteria among the 100 CKD patients
| <50 years (35) | 38.1 (10.7) | 47.9 (6.4) | 63.5 (13.5) |
| ≥50 years(65) | 29.9 (9.5) | 45.2 (9.5) | 55.3 (12.0) |
| <0.001 | 0.08 | 0.003 | |
| Male (54) | 35.0 (9.9) | 49.2 (7.6) | 61.3 (9.4) |
| Female(46) | 32.4 (9.4) | 41.2 (6.2) | 58.9 (8.5) |
| 0.003 | 0.002 | 0.004 | |
| <Secondary school (49) | 32.0 (10.2) | 44.6 (7.5) | 54.6 (11.8) |
| ≥Secondary school (51) | 33.5 (10.7) | 47.6 (6.7) | 61.6 (13.5) |
| 0.5 | 0.04 | 0.007 | |
| Not working (43) | 29.7 (9.7) | 45.2 (7.2) | 45.6 (11.5) |
| Working (57) | 35.1 (10.8) | 46.8 (7.3) | 60.9 (13.7) |
| 0.01 | 0.3 | 0.02 | |
| No(64) | 33.7 (10.9) | 46.3 (7.3) | 59.1 (13.9) |
| Yes (36) | 31.0 (10.0) | 45.8 (7.5) | 54.0 (11.0 |
| 0.2 | 0.7 | 0.04 | |
| No (58) | 35.1 (10.0) | 42.8 (7.1) | 61.1 (10.9) |
| Yes(42) | 32.2 (9.3) | 45.8 (7.5) | 57.0 (9.2) |
| 0.001 | 0.005 | 0.01 | |
| Stage 3 (44) | 36.1 (10.2) | 48.7 (6.3) | 61.7 (9.5) |
| Stage 4 (56) | 32.8 (9.3) | 44.8 (7.3) | 59.5 (8.7) |
| 0.001 | 0.01 | 0.02 | |
Correlation between the domains and the overall health rate of the Arabic version of KDQOL-SFversion 1.3 among the 100 CKD patients
| · | 0.28 | 0.005 |
| · | 0.34 | <0.001 |
| · | 0.31 | 0.003 |
| · | 0.08 | 0.44 |
| · | 0.21 | 0.04 |
| · | 0.29 | 0.003 |
| · | 0.19 | 0.37 |
| · | 0.3 | 0.002 |
| · | 0.23 | 0.02 |
| · | 0.16 | 0.12 |
| · | 0.29 | 0.004 |
| · | 0.30 | 0.002 |
| · | 0.26 | 0.009 |
| · | 0.32 | 0.001 |
| · | -0.017 | 0.87 |
| · | 0.14 | 0.17 |
| · | 0.27 | 0.008 |
| · | 0.18 | 0.07 |
Correlation between the kidney disease targeted scales and SF-36 main composite summaries of the Arabic version of KDQOL-SF1.3 among the 100 CKD patients
| · | 0.61 (<0.001) | 0.40 (<0.001) |
| · | 0.45 (<0.001) | 0.24 (0.02) |
| · | 0.68 (<0.001) | 0.53 (<0.001) |
| · | 0.68 (<0.001) | 0.37 (<0.001) |
| · | 0.67 (<0.001) | 0.40 (<0.001) |
| · | 0.38 (<0.001) | 0.55 (<0.001) |
| · | 0.45 (<0.001) | 0.10 (0.35) |
| · | 0.61 (<0.001) | 0.28 (0.006) |
| · | 0.24 (0.02) | 0.24 (0.02) |
| · | 0.41 (<0.001) | 0.32 (0.001) |
Country comparison of internal consistency reliability of the KDQOL-SFversion 1.3 questionnaire
| · | 0.81 | 0.84 | 0.81 | 0.92 | 0.80 |
| · | 0.73 | 0.82 | 0.79 | 0.89 | 0.76 |
| · | 0.88 | 0.83 | 0.81 | 0.86 | 0.80 |
| · | 0.28 | 0.83 | 0.69 | 0.71 | 0.39 |
| · | 0.60 | 0.68 | 0.73 | 0.74 | 0.83 |
| · | 0.23 | 0.61 | 0.35 | 0.77 | 0.39 |
| · | 0.90 | 0.89 | 0.92 | 0.92 | 0.95 |
| · | 0.90 | 0.90 | 0.61 | 0.77 | 0.72 |
| · | 0.88 | 0.89 | 0.76 | 0.76 | 0.67 |
| · | 0.95 | 0.92 | 0.90 | 0.93 | …. |
| · | 0.76 | 0.87 | 0.88 | 0.89 | …. |
| · | 0.87 | 0.90 | 0.83 | 0.88 | …. |
| · | 0.83 | 0.78 | 0.80 | 0.74 | …. |
| · | 0.70 | 0.80 | 0.84 | 0.73 | …. |
| · | 0.83 | 0.86 | 0.92 | 0.79 | …. |
| · | 0.88 | 0.87 | 0.73 | 0.82 | …. |
| · | 0.81 | 0.90 | 0.81 | 0.79 | …. |
1 Data by Hays et al (1994).
2 Data by Green et al (2001).
3 Data by Pakpour et al (2011).
4 Data by Korevaar et al (2002).